RecruitingPsoriasis Vulgaris
Correction of Psoriatic T Cell Signatures by Deucravacitinib
Eligible age
18–75 yrs
Accepts
All genders
Locations
1 state
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
This study aims to assess cutaneous and blood immune cell function of patients with psoriasis before and after initiation of treatment with the Tyrosine kinase 2 (TYK2) blocker, deucravacitinib.
Sponsor: University of California, San Francisco
You may qualify if…
- ✓ 1. 18 years of age or older
- ✓ 2. Patients with moderate-severe psoriasis (BSA \>= 10%, PASI \>=12, static Physician's Global Assessment (sPGA) 3 and above)
You may not qualify if…
- ✕ 1. taking systemic immunosuppressives in the last 12 weeks
- ✕ 2. pregnancy
- ✕ 3. severe immunodeficiency (either from genetic or infectious causes).
- ✕ 4. tuberculosis or other active serious infection
- ✕ 5. active systemic malignancy.
- ✕ 6. breast-feeding
- ✕ 7. Presence of a condition or abnormality that in the opinion of the Investigator would compromise the safety of the patient or the quality of the data.
Where it's recruiting
California
San Francisco
Source: ClinicalTrials.gov · NCT05858645 · last updated 2026-06-04